title: [Cycloferon in therapy of hyperplastic laryngitis for decrease of the number of relapses].
abstract: The article describes the clinical forms of chronic hyperplastic laryngitis, characterized by persistent and recurrent course, a tendency to the formation of oncological pathology, at the expense of hyperplastic changes in the larynx, leading to a malignancy of the inflammatory process. It was demonstrated the bacterization of larynx by Epstein-Barr virus (EBV) and Mycoplasma in imbalance of system of interferon. Clinical recovery, depending on the clinical form of the disease, using cycloferon, was observed in 57.4% of patients. The inclusion in the complex of the medical support of chronic hyperplastic laryngitis inducer of interferon - cycloferon, provided the reduction of the number of relapses.
authors.forename: S S
authors.initials: SS
authors.lastname: Grigorian
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: E V
authors.initials: EV
authors.lastname: Demchenko
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
mesh_terms: D000166:Acridines / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D002908:Chronic Disease; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006965:Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007369:Interferon Inducers / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D007827:Laryngitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007830:Larynx / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D009174:Mycoplasma / Q000187:drug effects / Q000254:growth & development; D009175:Mycoplasma Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D055502:Secondary Prevention
chemical_list: D000166:Acridines; D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D007369:Interferon Inducers; D016898:Interferon-alpha; D007371:Interferon-gamma; C026430:10-carboxymethyl-9-acridanone